A new review notes advances and remaining questions, and calls for better incorporation of data from veterans.
Immunotherapy has ushered in a new era in the treatment of non–small cell lung cancer (NSCLC), but a new review article notes significant questions remain in terms of understanding which patients benefit most from the therapy and how best to administer it.
Investigators discussed the latest findings in Seminars in Oncology. “Therapeutic decisions in advanced (metastatic) NSCLC have become more complex as the number of available treatment options has increased,” they noted.
Factors such as the presence of driver mutations and programmed death-ligand 1 (PD-L1) expression level are key data points in making treatment decisions, they said. In addition, patient performance status and comorbidities must be considered.
In patients with PD-L1 expression levels at or above 50%, single-agent checkpoint inhibitors such as pembrolizumab (Keytruda), cemiplimab (Libtayo), and atezolizumab (Tecentriq), have been shown to work well vs chemotherapy, the authors said. However, in patients with PD-L1 levels of 1% to 49%, evidence suggests overall survival (OS) rates from single-agent PD-L1 inhibition are lower. Thus, chemo-immunotherapy combinations are preferred for such patients, so long as they can tolerate the therapy.
The authors said dual PD-L1 inhibition and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibition is also available and is drawing significant attention as a chemotherapy-free treatment option. Yet, they said no head-to-head trial findings are available showing how dual inhibition performs against pembrolizumab alone or with chemotherapy. In the absence of such a trial, existing data suggest dual inhibition is not superior. Thus, they said, they tend to prefer pembrolizumab-based combinations without a CTLA-4 inhibitor, “unless there are compelling reasons or strong patient preference to avoid cytotoxic chemotherapy.”
In nonmetastatic cases, surgery and radiation or concurrent chemo-radiation are the “mainstay of curative-intent treatment of NSCLC,” the authors said. But there have been clinical trials evaluating the use of immune checkpoint inhibitors (ICIs) in these patients.
“Overall, the results of these nonmetastatic ICI trials are encouraging and expand the population of patients who may derive benefit from ICI therapy,” they wrote. “However, much remains to be elucidated.”
Those questions include whether EGFR mutational status matters in the regimen’s efficacy, they said. Looking forward, the authors said the current body of scientific evidence suffers from a lack of representation of key demographic groups. Although patients who are Black have a lower incidence of lung cancer compared with non-Hispanic Whites, they face a lower 5-year survival rate. One reason, the authors said, could be their inequitable representation in clinical trials.
They said the VA system offers a unique opportunity to incorporate underrepresented groups into future studies.
“VA health care system patients were found to be more likely to be African American and had a lower annual income when compared to the general US population,” they said. “On average, veterans have been found to have a higher comorbidity burden.”
Moreover, lung cancer is prevalent in the VA health system, many patients in the system are being treated with immunotherapy, and their data can provide for meaningful study, including real-world data.
The investigators noted that a previous retrospective analysis of real-world VA data showed veterans receiving ICI therapy for multiple tumor types had worse survival outcomes than those of the pivotal clinical trials, but those outcomes still exceeded standard-of-care therapies.
“These signals make it imperative to continue to generate a higher level of evidence with the gold standard of prospective randomized controlled trials with the inclusion of the veteran population,” they concluded.
Reference
Huang Q, Kemnade J, Cornwell L, Kheradmand F, Sabichi A, Das D. Non-small cell lung cancer in the era of immunotherapy. Semin Oncol. Published online July 8, 2022. doi:10.1053/j.seminoncol.2022.06.009
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More